Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."


USP General Chapter <797> Pharmaceutical Compounding – Sterile Preparations

Latest Updates  on USP <797> On September 23, 2019, the United States Pharmacopeia has announced that,…

read more

What you need to comply with the pending USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations

3 key compliance criteria While the implementation date of the new USP General Chapter <797>…

read more

2019 AAOA Advanced Course in Allergy & immunology Optional USP 797 Compliance Workshop

Cost: $125 for AAOA members and $300 for non-members* in addition to AAOA Advanced Course registration…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/19: Research Grant Cycle
Learn more

02/15/20: Crowdsourcing for 2020 Scottsdale
Learn more

02/15/20: Call for Proposals
Learn more

04/01/20: Fellow Exam Application Deadline
Learn more

06/01/20: Research Grant Cycle
Learn more

06/26/20: Membership Application Deadline to be eligible for AAOA Member rate for the 2020 Basic Course Learn more

09/11/20: Membership Application Deadline to be voted in at the 2020 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2020 Annual Meeting Learn more


Here is What You Missed...

2019 New Orleans was an outstanding success?  With over 500 participants, our AAOA members left New Orleans re-energized, re-freshed, and re-engaged.  The program offered something for everyone — from cutting edge clinical content to every day how to’s for practice management efficiencies. Read More


IFAR Impact Factor: 2.454


Now Available

Changes in Managing Practices


Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2020 Basic Course in Allergy & Immunology
July 9-11 | Orlando, FL
Learn More and Register

2020 AAOA Annual Meeting
October 23-25| Scottsdale, AZ
Learn More and Register

2020 Advanced Course in Allergy & Immunology
December 9-12 | Vail, CO
Save the Date

AAOA Clinical Insights
Learn More and Register

NEW!!! USP 797 Online Module
Learn More and Register


AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More


Off to College: Tips for Managing Allergies

Heading to college is an exciting time. What are the best ways for students to avoid exacerbation of their symptoms as they enter the hallowed halls of higher learning?

Read More

College Allergy Symptoms Treatment Back to Shcool

News and Updates

First Drug for Treatment of Peanut Allergy for Children is Approved by FDA

“Peanut allergy affects approximately 1 million children in the U.S. and only 1 out of…

read more

Revised CPT Code for 2020

The following revisions and additions to Current Procedural Terminology (CPT ® American Medical Association) codes related…

read more

The MIPS Update from the Centers for Medicare and Medicaid Services

The MIPS 2019 Data Submission Period is Now Open MIPS Eligible Clinicians Can Start Submitting…

read more

Microscope 275984 640

New Drug Treatments for Allergies

Food allergies are a growing health concern with a significant increase in reported prevalence. Allergic reactions to food can produce life-threatening anaphylaxis. Peanut allergy in particular is a significant public health problem with no proven treatment nor a cure at the present time.

Peanut allergy often remains a life-long problem for many individuals, as less than 25% of peanut allergic patients are expected to regain tolerance. Current recommendations for management include strict avoidance and a prescription for an auto-injectable form of epinephrine.

The increase in prevalence of peanut allergy occurred during a period of time when there was conflicting guidance regard- ing preventative measures for the development of peanut allergy.

Prior to the year 2000, there were no guidelines regarding the timing for the introduction of peanut-containing products nor were there any purposeful strategies to delay the introduction of peanut-containing products to try to prevent the development of allergic disease. But in 2000, the American Academy of Pediatrics recommended that “solid foods should not be introduced into the diet of high-risk infants until 6 months of age…and peanuts…until years of age.”

This recommendation was reversed in 2008. At that time, AAP recommended that “the introduction of solid foods not be delayed past 4-6 months of age”. However they did not make any updated recommendations regarding the introduction of peanut-containing products.

The Learning Early About Peanut allergy (LEAP) study demonstrated that peanut-containing products can be safely introduced to high-risk infants between the ages of 4 to 11 months and that there is a monumental potential for peanut allergy prevention.

The National Institutes of Allergy and Infectious Diseases (NIAID) recently published an addendum guideline regarding the prevention of peanut allergy in the US based on the findings from the LEAP study. [Togias A et al. Addendum guidelines for the prevention of peanut allergy in the United States. J Allergy CliniImmunol.
2017 Jan;139(1):29-44.]

The NIAID-sponsored guidelines include the following three addendum recommendations:

Leave a Reply

Your email address will not be published. Required fields are marked *